2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

1459 Defining the immunoproteasome as a lineage-selective dependency in lymphoid malignancies

Tianhao Yin, Jodi Forward, MD2, Kadriye Nehir Cosgun, PhD3, Mark E Robinson, PhD4, Ulrike Seifert5, Clemens Cammann6, Markus Müschen, MD-PhD7
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Pediatrics, Section of Hematology-Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Institute of Medical Microbiology, Greifswald, Germany
6 Institute of Medical Microbiology, Greifswald, Germany
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States

Background and Significance. In solid tumors, activating β-catenin mutations commonly drive oncogenic canonical WNT-signaling. In contrast, B-lymphoid malignancies lack recurrent lesions in the β-catenin degradation pathway and instead have evolved and critically depend on on continuous, high-efficiency β-catenin protein degradation. We recently demonstrated that disruption of high-efficiency β-catenin protein degradation induces the formation of repressive β-catenin complexes and acute leukemia cell death (Cosgun et al., Nat Cancer 2026). However, the components of β-catenin complexes and the mechanism of high-efficiency degradation in lymphocytes remained unclear. Analysis of gene-expression profiles across cancer cell lines (DepMap Public 25Q3) revealed that lymphoid malignancies express the highest levels of all three immunoproteasome catalytic subunits, PSMB8, PSMB9, and PSMB10, relative to other lineages (P<0.0001 for each). We therefore hypothesized that the immunoproteasome represents a lineage-specific dependency that is selectively required for β-catenin homeostasis in lymphoid malignancies.

Results: To define the relationship between immunoproteasome activity and β-catenin degradation, we evaluated two selective PSMB8/PSMB9 immunoproteasome inhibitors, ONX-0914 and zetomipzomib. Zetomipzomib has completed Phase 1b/2 clinical studies in lupus nephritis and autoimmune hepatitis and demonstrated a favorable safety profile. In viability assays (CellTiter-Glo, day 3), zetomipzomib induced uniform, near-complete killing of seven lymphoid cell lines and PDX spanning B-cell acute lymphoblastic leukemia (B-ALL), T-ALL, and mantle cell lymphoma, with a median IC50 of 56 nM. By comparison, four solid-tumor cell lines exhibited a median IC50 of 916 nM, defining a 16-fold lineage-selectivity window. ONX-0914 produced comparable lineage-selective toxicity. Importantly, patient-derived B-ALL cells from treatment-naïve and relapsed specimens responded similarly to immunoproteasome inhibition, suggesting potential activity in chemotherapy-refractory disease. In patient-derived B-ALL patient-derived xenograft (PDX) cells, both inhibitors induced marked β-catenin accumulation, implicating the immunoproteasome in constitutive β-catenin turnover. Consistent with this observation, deletion of β-catenin in BCR::ABL1 B-ALL cells partially rescued zetomipzomib- and ONX-0914-induced toxicity, while indicating that additional β-catenin-independent mechanisms contribute to their activity.

To genetically model immunoproteasome dependency in B-ALL, we generated BCR::ABL1-transformed murine B-ALL cells harboring tamoxifen-inducible Psmb8 deletion and shRNA-mediated Psmb9 suppression. Efficient depletion of the respective proteins was confirmed by western blotting. Unexpectedly, loss of Psmb8 or Psmb9, individually or in combination, neither impaired cell viability nor stabilized β-catenin. However, Psmb8-deficient cells were fully resistant to zetomipzomib at concentrations up to 250 nM (wild-type IC50, 150 nM), while largely retaining sensitivity to the constitutive proteasome inhibitor bortezomib. These findings demonstrate that zetomipzomib activity specifically depends on PSMB8 expression. Western blot analysis further showed that Psmb8 deletion substantially increased PSMB5 protein abundance, consistent with adaptive compensation by the constitutive proteasome. Future studies will define the molecular basis for the divergent consequences of acute pharmacologic inhibition and genetic disruption of the immunoproteasome.

Conclusions: These findings identify the immunoproteasome as a lineage-selective pharmacologic dependency across lymphoid malignancies and establish β-catenin stabilization as one mechanism contributing to immunoproteasome inhibitor-induced toxicity. The divergent outcomes of acute pharmacologic inhibition and genetic disruption reveal substantial proteasome plasticity, including compensatory induction of constitutive proteasome subunits, as a potential mechanism of resistance. Given the clinical evaluation and favorable safety profile of zetomipzomib in Phase 1b/2 trials for autoimmune disorders, immunoproteasome inhibition-either alone or in combination with low-dose constitutive proteasome inhibition-represents a promising lineage-selective therapeutic strategy for lymphoid malignancies.

Tianhao Yin: No relevant conflicts of interest to declare.